The 96-well assay methodology offers a robust framework for assessing the potential of HSP47 inhibitors in platelet aggregation, contributing to the development of refined therapeutic strategies to combat thrombotic diseases through precise dose management [6,52]. The gene discussed is SERPINH1; the disease is thrombotic disease.